{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:34:03Z","timestamp":1780554843701,"version":"3.54.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T00:00:00Z","timestamp":1243296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-244x-9-25","type":"journal-article","created":{"date-parts":[[2009,5,27]],"date-time":"2009-05-27T02:15:09Z","timestamp":1243390509000},"source":"Crossref","is-referenced-by-count":25,"title":["A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study"],"prefix":"10.1186","volume":"9","author":[{"given":"James M","family":"Prosser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Yard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor I","family":"Galynker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,5,26]]},"reference":[{"key":"573_CR1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Text Revision","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Text Revision. 2000, Washington, DC: American Psychiatric Association, Fourth","edition":"Fourth"},{"issue":"4","key":"573_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11920-006-0063-6","volume":"8","author":"MJ Zvolensky","year":"2006","unstructured":"Zvolensky MJ, Bernstein A, Marshall EC, Feldner MT: Panic attacks, panic disorder, and agoraphobia: associations with substance use, abuse, and dependence. Curr Psychiatry Rep. 2006, 8 (4): 279-85. 10.1007\/s11920-006-0063-6.","journal-title":"Curr Psychiatry Rep"},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/archpsyc.1997.01830190069007","volume":"54","author":"JD Coplan","year":"1997","unstructured":"Coplan JD, Poppa LA, Pine D: Clinical improvement with Fluoxetine therapy and noradrenergic function in patients with panic disorders. Arch Gen Psychiatry. 1997, 54: 643-648.","journal-title":"Arch Gen Psychiatry"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1523\/JNEUROSCI.4921-03.2004","volume":"24","author":"A Neumeister","year":"2004","unstructured":"Neumeister A, Bain E, Nugent AC: Reduced serotonin A1 receptor binding in panic disorder. J Neurosci. 2004, 24: 589-591. 10.1523\/JNEUROSCI.4921-03.2004.","journal-title":"J Neurosci"},{"issue":"1","key":"573_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.npp.1300880","volume":"31","author":"E Maron","year":"2006","unstructured":"Maron E, Shlik J: Serotonin function in panic disorder: important, but why?. Neuropsychopharmacology. 2006, 31 (1): 1-11.","journal-title":"Neuropsychopharmacology"},{"issue":"suppl 14","key":"573_CR6","first-page":"22","volume":"65","author":"HG Westenberg","year":"2004","unstructured":"Westenberg HG, Leibowitz MR: Overview of Panic and Social Anxiety Disorders. J Clin Psychiatry. 2004, 65 (suppl 14): 22-26.","journal-title":"J Clin Psychiatry"},{"key":"573_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-1781(01)00265-7","volume":"103","author":"GM Asnis","year":"2001","unstructured":"Asnis GM, Hameedi FA, Goddard AW: Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res. 2001, 103: 1-14. 10.1016\/S0165-1781(01)00265-7.","journal-title":"Psychiatry Res"},{"issue":"suppl 4","key":"573_CR8","first-page":"23","volume":"66","author":"M Pollack","year":"2005","unstructured":"Pollack M: The pharmacotherapy of panic disorder. J Clin Psychiatry. 2005, 66 (suppl 4): 23-27.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"573_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/da.20218","volume":"24","author":"MH Pollack","year":"2007","unstructured":"Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety. 2007, 24 (1): 1-14. 10.1002\/da.20218.","journal-title":"Depress Anxiety"},{"issue":"1","key":"573_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4088\/JCP.v66n0105","volume":"66","author":"DV Sheehan","year":"2005","unstructured":"Sheehan DV, Burnham DB, Iyengar MK, Perera P: Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry. 2005, 66 (1): 34-40.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"573_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-244X-4-16","volume":"11","author":"PN Dannon","year":"2004","unstructured":"Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M: Three year naturalistic outcome study of panic disorder patients treated with paroxetine. BMC Psychiatry. 2004, 11 (4): 16-10.1186\/1471-244X-4-16.","journal-title":"BMC Psychiatry"},{"issue":"10","key":"573_CR12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1017\/S1092852900022379","volume":"9","author":"B Bandelow","year":"2004","unstructured":"Bandelow B, Ruther E: Treatment-resistant panic disorder. CNS Spectr. 2004, 9 (10): 725-39.","journal-title":"CNS Spectr"},{"issue":"3","key":"573_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1055\/s-2001-14283","volume":"34","author":"G Perna","year":"2001","unstructured":"Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L: A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001, 34 (3): 85-90. 10.1055\/s-2001-14283.","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"573_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-2000-11221","volume":"33","author":"C Toni","year":"2000","unstructured":"Toni C, Perugi G, Frare F, Mata B, Vitale B, Mengali F, Recchia M, Serra G, Akiskal HS: A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry. 2000, 33 (4): 121-31. 10.1055\/s-2000-11221.","journal-title":"Pharmacopsychiatry"},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1176\/ajp.155.1.36","volume":"155","author":"JC Ballenger","year":"1998","unstructured":"Ballenger JC, Wheadon DE, Steiner M: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorders. Am J Psychiatry. 1998, 155: 36-42.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"573_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1586\/14737175.5.2.259","volume":"5","author":"M Lader","year":"2005","unstructured":"Lader M: Management of panic disorder. Expert Rev Neurother. 2005, 5 (2): 259-66. 10.1586\/14737175.5.2.259.","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"573_CR17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1017\/S1461145705005201","volume":"8","author":"A Bakker","year":"2005","unstructured":"Bakker A, van Balkom AJ, Stein DJ: Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol. 2005, 8 (3): 473-82. 10.1017\/S1461145705005201.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"8 Suppl 1","key":"573_CR18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1017\/S109285290000691X","volume":"8","author":"MH Pollack","year":"2003","unstructured":"Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP: WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003, 8 (8 Suppl 1): 17-30.","journal-title":"CNS Spectr"},{"issue":"1","key":"573_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/01.jcp.0000195108.01898.17","volume":"26","author":"G Sepede","year":"2006","unstructured":"Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006, 26 (1): 45-9. 10.1097\/01.jcp.0000195108.01898.17.","journal-title":"J Clin Psychopharmacol"},{"key":"573_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.euroneuro.2005.04.006","volume":"15","author":"RD Goodwin","year":"2005","unstructured":"Goodwin RD, Faravelli C, Rosi S, Cosci F, Truglia E, de Graaf R, Wittchen HU: The epidemiology of panic disorder and agoraphobia in Europe. Eur Neurpsychopharmacol. 2005, 15: 435-443. 10.1016\/j.euroneuro.2005.04.006.","journal-title":"Eur Neurpsychopharmacol"},{"issue":"6 Suppl 2","key":"573_CR21","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.1097\/00004714-199812001-00004","volume":"18","author":"K Rickels","year":"1998","unstructured":"Rickels K, Schweizer E: Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol. 1998, 18 (6 Suppl 2): 12S-18S. 10.1097\/00004714-199812001-00004.","journal-title":"J Clin Psychopharmacol"},{"key":"573_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","volume":"158","author":"RR Conley","year":"2001","unstructured":"Conley RR, Mahmoud R: A randomized, double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001, 158: 765-774. 10.1176\/appi.ajp.158.5.765.","journal-title":"Am J Psychiatry"},{"key":"573_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/00004850-200015060-00005","volume":"15","author":"J Peuskens","year":"2000","unstructured":"Peuskens J, Van Baelen B, De Smedt C, Lemmens P: Effects of risperidone on affective symtpoms in patients with schizophrenia. Int Clin Psychophamacol. 2000, 15: 343-49. 10.1097\/00004850-200015060-00005.","journal-title":"Int Clin Psychophamacol"},{"key":"573_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.4088\/JCP.v61n0512c","volume":"61","author":"M Kaplan","year":"2000","unstructured":"Kaplan M: Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry. 2000, 61: 388-9.","journal-title":"J Clin Psychiatry"},{"key":"573_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4088\/JCP.v66n0420f","volume":"66","author":"I Galynker","year":"2005","unstructured":"Galynker I, Khan A, Grebchenko Y, Ten A, Malaya L, Yanowitch P, Cohen LJ: Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry. 2005, 66: 544-","journal-title":"J Clin Psychiatry"},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00019442-200501000-00014","volume":"13","author":"A Morinigo","year":"2005","unstructured":"Morinigo A, Blanco M, Labrador J, Martine J, Noval D: Risperidone for resistant anxiety in elderly persons. Am J Geriatr Psychiatry. 2005, 13: 81-82.","journal-title":"Am J Geriatr Psychiatry"},{"key":"573_CR27","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.4088\/JCP.v66n1016","volume":"66","author":"O Brawman-Mintzer","year":"2005","unstructured":"Brawman-Mintzer O, Knapp RG, Nietert PJ: Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005, 66: 1321-1325.","journal-title":"J Clin Psychiatry"},{"key":"573_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","volume":"57","author":"CJ McDougle","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000, 57: 794-801. 10.1001\/archpsyc.57.8.794.","journal-title":"Arch Gen Psychiatry"},{"key":"573_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1017\/S1461145703003730","volume":"63","author":"E Hollander","year":"2003","unstructured":"Hollander E, Baldini Rossi N, Sood E: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003, 63: 397-401. 10.1017\/S1461145703003730.","journal-title":"Int J Neuropsychopharmacol"},{"key":"573_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.4088\/JCP.v66n0610","volume":"66","author":"X Li","year":"2005","unstructured":"Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR: Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry. 2005, 66: 736-43.","journal-title":"J Clin Psychiatry"},{"key":"573_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","volume":"15","author":"S Erzegovesi","year":"2005","unstructured":"Erzegovesi S, Guglielmo E, Silipriandi F, Bellodi L: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol. 2005, 15: 69-74. 10.1016\/j.euroneuro.2004.04.004.","journal-title":"Eur Neuropsychopharmacol"},{"key":"573_CR32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.biopsych.2004.11.039","volume":"57","author":"G Bartzokis","year":"2004","unstructured":"Bartzokis G, Lu PH, Turner J, Mintz J, Saunders CS: Adjunctive risperidone in the treatment of chronic combat-related post-traumatic stress disorder. Biol Psychiatry. 2004, 57: 474-479. 10.1016\/j.biopsych.2004.11.039.","journal-title":"Biol Psychiatry"},{"key":"573_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00004850-200301000-00001","volume":"18","author":"MB Hamner","year":"2002","unstructured":"Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW: Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol. 2002, 18: 1-8. 10.1097\/00004850-200301000-00001.","journal-title":"Int Clin Psychopharmacol"},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00004714-200304000-00012","volume":"23","author":"EP Monnelly","year":"2003","unstructured":"Monnelly EP, Ciraulo DA, Knapp C, Keane T: Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol. 2003, 23: 193-6. 10.1097\/00004714-200304000-00012.","journal-title":"J Clin Psychopharmacol"},{"key":"573_CR35","doi-asserted-by":"publisher","first-page":"922","DOI":"10.4088\/JCP.v66n0716","volume":"66","author":"D Kozaric-Kovacic","year":"2005","unstructured":"Kozaric-Kovacic D, Pivac N, Muck-Seler D, Rothbaum BO: Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry. 2005, 66: 922-927.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 8","key":"573_CR36","first-page":"11","volume":"59","author":"Y Lecrubier","year":"1998","unstructured":"Lecrubier Y: The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry. 1998, 59 (Suppl 8): 11-14.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 4","key":"573_CR37","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1097\/00004850-199804004-00004","volume":"13","author":"DL Dunner","year":"1998","unstructured":"Dunner DL: The issue of comorbidity in the treatment of panic. Int Clin Psychopharmacol. 1998, 13 (Suppl 4): S19-24.","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"573_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/archpsyc.55.9.801","volume":"55","author":"RC Kessler","year":"1998","unstructured":"Kessler RC, Stang PE, Wittchen HU, Ustun TB, Roy-Burne PP, Walters EE: Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry. 1998, 55 (9): 801-8. 10.1001\/archpsyc.55.9.801.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"573_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.4088\/JCP.v63n0207","volume":"63","author":"TK Melartin","year":"2002","unstructured":"Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET: Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study. J Clin Psychiatry. 2002, 63 (2): 126-34.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"573_CR40","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/archpsyc.1994.03950110086011","volume":"51","author":"MM Weissman","year":"1994","unstructured":"Weissman MM, Wickramaratne P, Adams PB, Lish JD, Horwath E, Charney D, Woods SW, Leeman E, Frosch E: The relationship between panic disorder and major depression. A new family study. Arch Gen Psychiatry. 1994, 51 (11): 926-7.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 1","key":"573_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/1520-6394(2000)12:1+<69::AID-DA9>3.0.CO;2-K","volume":"12","author":"J Kaufman","year":"2000","unstructured":"Kaufman J, Charney D: Comorbidity of mood and anxiety disorders. Depress Anxiety. 2000, 12 (Suppl 1): 69-76. 10.1002\/1520-6394(2000)12:1+<69::AID-DA9>3.0.CO;2-K.","journal-title":"Depress Anxiety"},{"issue":"Suppl 1","key":"573_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0022-3956(93)90015-T","volume":"27","author":"J Reich","year":"1993","unstructured":"Reich J, Warshaw M, Peterson LG, White K, Keller M, Lavori P, Yonkers KA: Comorbidity of panic and major depressive disorder. J Psychiatr Res. 1993, 27 (Suppl 1): 23-33. 10.1016\/0022-3956(93)90015-T.","journal-title":"J Psychiatr Res"},{"key":"573_CR43","unstructured":"Gorman J, Shear K, Cowley D, Cross CD, March J, Roth W, Shehi M, Wang PS: Practice guidelines for the treatment of patients with panic disorder. [ http:\/\/www.psychiatryonline.com\/pracGuide\/pracGuideTopic_9.aspx ]"},{"key":"573_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960, 23: 56-62. 10.1136\/jnnp.23.1.56.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"573_CR45","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2044-8260.1967.tb00530.x","volume":"6","author":"M Hamilton","year":"1967","unstructured":"Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967, 6 (4): 278-96.","journal-title":"Br J Soc Clin Psychol"},{"key":"573_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.psychres.2003.11.003","volume":"125","author":"S Moritz","year":"2004","unstructured":"Moritz S, Meier B, Hand I, Schick M, Jahn H: Dimensional structure of the Hamilton Depression Rating Scale in patients with obsessive-compulsive disorder. Psychiatry Res. 2004, 125: 171-80. 10.1016\/j.psychres.2003.11.003.","journal-title":"Psychiatry Res"},{"key":"573_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol. 1959, 32: 50-55.","journal-title":"Br J Med Psychol"},{"issue":"5","key":"573_CR48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0022-3956(01)00028-0","volume":"35","author":"MK Shear","year":"2001","unstructured":"Shear MK, Rucci P, Williams J, Frank E, Grochocinski V, Bilt Vander J, Houck P, Wang T: Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res. 2001, 35 (5): 293-6. 10.1016\/S0022-3956(01)00028-0.","journal-title":"J Psychiatr Res"},{"issue":"8","key":"573_CR49","first-page":"309","volume":"48","author":"A Raj","year":"1987","unstructured":"Raj A, Sheehan DV: Medical evaluation of panic attacks. J Clin Psychiatry. 1987, 48 (8): 309-13.","journal-title":"J Clin Psychiatry"},{"key":"573_CR50","volume-title":"ECDEU Assessment Manual Psychopharmacology, revised National Institute of Mental Health, Rockville MD","author":"W Guy","year":"1976","unstructured":"Guy W: Clinical Global Impressions. ECDEU Assessment Manual Psychopharmacology, revised National Institute of Mental Health, Rockville MD. 1976"},{"key":"573_CR51","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archpsyc.1993.01820210073009","volume":"50","author":"RD Gibbons","year":"1993","unstructured":"Gibbons RD, Hediker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB, Shea T, Imber S, Stotsky SM, Watkins JT: Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry. 1993, 50: 739-750.","journal-title":"Arch Gen Psychiatry"},{"key":"573_CR52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/sim.4780070131","volume":"7","author":"NM Laird","year":"1988","unstructured":"Laird NM: Missing data in longitudinal studies. Stat Med. 1988, 7: 305-315. 10.1002\/sim.4780070131.","journal-title":"Stat Med"},{"issue":"1\u20132","key":"573_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/biomet\/52.1-2.203","volume":"52","author":"EA Gehan","year":"1965","unstructured":"Gehan EA: A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965, 52 (1\u20132): 203-223.","journal-title":"Biometrika"},{"key":"573_CR54","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.4088\/JCP.v67n0902","volume":"67","author":"K Gao","year":"2006","unstructured":"Gao K, Muzina D, Gajwani P, Calabrese JR: Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders. J Clin Psychiatry. 2006, 67: 1327-1340.","journal-title":"J Clin Psychiatry"},{"key":"573_CR55","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4088\/JCP.v67n0307","volume":"67","author":"NM Simon","year":"2006","unstructured":"Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian JM, Kinrys G, Pollack MH: An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006, 67: 381-387.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"573_CR56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00004850-200609000-00005","volume":"21","author":"PR Padala","year":"2006","unstructured":"Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, Din AU, Wilson DR, Petty F: Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol. 2006, 21 (5): 275-80. 10.1097\/00004850-200609000-00005.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"573_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF02245439","volume":"114","author":"AA Megens","year":"1994","unstructured":"Megens AA: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology Berl. 1994, 114 (1): 9-23. 10.1007\/BF02245439.","journal-title":"Psychopharmacology Berl"},{"issue":"3","key":"573_CR58","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF02251280","volume":"110","author":"S Nyberg","year":"1993","unstructured":"Nyberg S, Farde L, Eriksson L, Halldin C, Eriksson B: 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology Berl. 1993, 110 (3): 265-72. 10.1007\/BF02251280.","journal-title":"Psychopharmacology Berl"},{"issue":"Suppl","key":"573_CR59","first-page":"5","volume":"55","author":"JE Leysen","year":"1994","unstructured":"Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994, 55 (Suppl): 5-12.","journal-title":"J Clin Psychiatry"},{"key":"573_CR60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.pneurobio.2004.09.004","volume":"74","author":"MA Peeze","year":"2004","unstructured":"Peeze MA, Feldon J: Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol. 2004, 74: 301-320. 10.1016\/j.pneurobio.2004.09.004.","journal-title":"Prog Neurobiol"},{"key":"573_CR61","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0304-3940(96)12631-8","volume":"209","author":"M Yoshioka","year":"1996","unstructured":"Yoshioka M, Matsumoto M, Togshi H, Saito H: Effect of conditioned fear stress on dopamine release in the rat prefrontal cortex. Neurosci Lett. 1996, 209: 201-203. 10.1016\/0304-3940(96)12631-8.","journal-title":"Neurosci Lett"},{"key":"573_CR62","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1523\/JNEUROSCI.15-04-03118.1995","volume":"15","author":"N Ladurelle","year":"1995","unstructured":"Ladurelle N, Roques BP, Dauge V: The transfer of rats from a familial to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens. J Neurosci. 1995, 15: 3118-3127.","journal-title":"J Neurosci"},{"key":"573_CR63","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/(SICI)1098-2396(199611)24:3<240::AID-SYN6>3.0.CO;2-E","volume":"24","author":"K Wedzony","year":"1996","unstructured":"Wedzony K, Mackowiak M, Fihal K, Golembiowska K: Evidence that conditioned stress enhances outflow of dopamine in the rat prefrontal cortex: a search for the influence of diazepam and 5-HT1A agonists. Synapse. 1996, 24: 240-247. 10.1002\/(SICI)1098-2396(199611)24:3<240::AID-SYN6>3.0.CO;2-E.","journal-title":"Synapse"},{"key":"573_CR64","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0091-3057(96)00064-0","volume":"55","author":"T Inoue","year":"1996","unstructured":"Inoue T, Tsuchiya K, Koyoma T: Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol Biochem Behav. 1996, 55: 195-201. 10.1016\/S0091-3057(96)00064-0.","journal-title":"Pharmacol Biochem Behav"},{"key":"573_CR65","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1254\/jjp.72.119","volume":"72","author":"K Ishida-Tokuda","year":"1996","unstructured":"Ishida-Tokuda K, Ohno Y, Sakamoto H, Ishibashi T, Wakabayashi A, Tojima R, Morita T, Nakamura M: Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats. Jpn J Pharmacol. 1996, 72: 119-126. 10.1254\/jjp.72.119.","journal-title":"Jpn J Pharmacol"},{"key":"573_CR66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s002130050914","volume":"143","author":"E Cavazutti","year":"1999","unstructured":"Cavazutti E, Bertoloni A, Vergoni AV, Arletti R, Poggioli R, Forgione A, Benelli A: 1-Sulpiride, at a low, non-neuroleptic dose, prevents conditioned fear stress-induced freezing behavior in rats. Psychopharmacology (Berl). 1999, 143: 20-23. 10.1007\/s002130050914.","journal-title":"Psychopharmacology (Berl)"},{"issue":"suppl 8","key":"573_CR67","first-page":"30","volume":"66","author":"P Blier","year":"2005","unstructured":"Blier P, Szabo ST: Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry. 2005, 66 (suppl 8): 30-40.","journal-title":"J Clin Psychiatry"},{"key":"573_CR68","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/syn.10009","volume":"42","author":"ST Szabo","year":"2001","unstructured":"Szabo ST, Blier P: Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus. Synapse. 2001, 42: 203-212. 10.1002\/syn.10009.","journal-title":"Synapse"},{"issue":"3","key":"573_CR69","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0022-3565(25)39339-0","volume":"266","author":"CA Stockmeier","year":"1993","unstructured":"Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY: Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther. 1993, 266 (3): 1374-1384.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"573_CR70","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1023\/A:1018786512676","volume":"35","author":"SK Dobscha","year":"1999","unstructured":"Dobscha SK, Delucchi K, Young ML: Adherence with referrals for outpatient follow-up from a VA psychiatric emergency room. Community Ment Health J. 1999, 35 (5): 451-8. 10.1023\/A:1018786512676.","journal-title":"Community Ment Health J"},{"key":"573_CR71","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1192\/bjp.176.2.160","volume":"176","author":"H Killaspy","year":"2000","unstructured":"Killaspy H, Banerjee S, King M, Lloyd M: Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome. Br J Psychiatry. 2000, 176: 160-5. 10.1192\/bjp.176.2.160.","journal-title":"Br J Psychiatry"},{"key":"573_CR72","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.0963-7214.2005.00386.x","volume":"14","author":"M Zvolensky","year":"2005","unstructured":"Zvolensky M, Bernstein A: Cigarette smoking and panic psychopathology. Curr Dir Psychological Sci. 2005, 14: 301-305. 10.1111\/j.0963-7214.2005.00386.x.","journal-title":"Curr Dir Psychological Sci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-9-25.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-9-25\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-9-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T13:25:41Z","timestamp":1739107541000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-9-25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,26]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-9-25","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1161350.621856","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,26]]},"article-number":"25"}}